Irbesartan and hydrochlorothiazide combination tablets -Recall

by | Jan 22, 2019 | Business Decision Making, cGMP, Communication, Community Service, Compliance, Ethics, FDA, FDA News, Guidelines, Manufacturing, Pharma, Process Improvement, Quality Systems, Recalls, Regulatory, Risk Assessment, Uncategorized |

Another voluntary recall of medications used in the treatment of high blood pressure has been issued due to the detection in the active pharmaceutical ingredient of an impurity considered probably carcinogenic to humans by the U.S. Environmental Protection Agency.

To read more, please click the following link

https://articles.masslive.com/news/index.ssf/2019/01/fda_another_blood_pressure_dru.amp

Thanks